Skyrizi (also known by its generic name risankizumab-rzaa) was approved by the FDA in April 2019 for the treatment of moderate-to-severe plaque psoriasis in adults. Skyrizi was approved by the FDA in January 2022 for the treatment of active psoriatic arthritis (PsA) in adults.

For both plaque psoriasis and PsA, Skyrizi is given by injection under the skin at week 0 (the first week of treatment) and week 4, and then every 12 weeks afterwards.

To learn more, please visit the Skyrizi website.